Who
Lale White
Director
Company insider
Files Form 4 as: Director, Cardiff Oncology; Director, CombiMatrix.
In numbers
- Trades disclosed
- 19
- Buys
- 4
- Sells
- 0
- Bought
- $149K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 12 Mar 2015
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 26 Jun 2025filed 27 Jun 2025 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 27 Jun 2024filed 1 Jul 2024 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,700 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,700 at $0.00 | filing |
| 19 Sep 2022filed 20 Sep 2022 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $25K15,000 at $1.64 | filing |
| 5 Jul 2022filed 6 Jul 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | $75K28,858 at $2.60 | filing |
| 5 Jul 2022filed 6 Jul 2022 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Code M | $75K28,858 at $2.60 | filing |
| 9 Mar 2022filed 10 Mar 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,800 at $0.00 | filing |
| 10 Jun 2021filed 14 Jun 2021 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 17 Jun 2020filed 19 Jun 2020 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,858 at $0.00 | filing |
| 14 May 2020filed 18 May 2020 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $100K69,930 at $1.43 | filing |
| 16 Apr 2020filed 1 May 2020 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,916 at $0.00 | filing |
| 14 Nov 2017filed 16 Nov 2017 | CombiMatrix | SEC FORM 4 Code D | —835 | filing |
| 14 Nov 2017filed 16 Nov 2017 | CombiMatrix | SEC FORM 4 Code U | —7,792 | filing |
| 10 May 2016filed 10 May 2016 | CombiMatrix | SEC FORM 4 Bought | $22K6,891 at $3.18 | filing |
| 9 May 2016filed 10 May 2016 | CombiMatrix | SEC FORM 4 Bought | $2,649901 at $2.94 | filing |
| 12 Mar 2015filed 16 Mar 2015 | CombiMatrix | SEC FORM 4 Code A | —12,528 at $0.00 | filing |
| 12 Mar 2015filed 16 Mar 2015 | CombiMatrixoption or derivative | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
News
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic LeukemiaCRDF · manilatimes.net · 21 Oct 2026Analyzing Cardiff Oncology (NASDAQ:CRDF) and Xencor (NASDAQ:XNCR)CRDF · themarketsdaily.com · 21 Oct 2026Contrasting Nektar Therapeutics (NASDAQ:NKTR) and Cardiff Oncology (NASDAQ:CRDF)CRDF · tickerreport.com · 12 Oct 2026
0 headlines in the last 90 days name Lale White; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.